A Phase 1 Open-Label Dose-Escalation and Cohort Expansion First-in-Human Study of the Safety Tolerability Activity and Pharmacokinetics of REGN3767 (anti-LAG-3 mAb) Administered Alone or in Combination with REGN2810 (anti-PD-1 mAb) in Patients with Ad

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Advanced Malignancies
  • Age: Between 18 - 99 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Patients with histologically or cytologically confirmed diagnosis of malignancy (including lymphoma) with demonstrated progression of a tumor for whom there is no available therapy likely to convey clinical benefit AND who have not been previously treated with a PD-1/PD-L1 inhibitor. 2. Patients with histologically or cytologically confirmed diagnosis tumors with measurable disease 3. Adequate organ and bone arrow function

You may not be eligible for this study if the following are true:

  • 1. Currently receiving treatment in another study, or has participated in a study of an investigational agent and received treatment, or used an investigational device within 4 weeks of start of study. 2. Prior treatment with any LAG-3 targeting biologic or small molecule. 3. Radiation therapy within 2 weeks prior to enrollment and not recovered to baseline from any adverse reaction due to radiation.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.